Skip to main content
. Author manuscript; available in PMC: 2015 Jan 17.
Published in final edited form as: N Engl J Med. 2014 May 31;371(3):213–223. doi: 10.1056/NEJMoa1400376

Figure 2. Subgroup Analyses of Progression-free Survival.

Figure 2

Shown are forest plots of hazard ratios for death or disease progression among subgroups of patients in the ibrutinib group and the ofatumumab group. The size of the circle is proportional to the size of the subgroup. The dashed vertical line indicates the overall treatment effect for all patients. The only test for heterogeneity that was significant was for geographic region (P = 0.02), although the treatment effect remained significant within each region (P<0.001). The Rai staging system ranges from 0 (low risk) to I or II (intermediate risk) to III or IV (high risk). The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 5, with higher scores indicating greater disability. Race was self-reported.